GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TuHURA Biosciences Inc.
The shares of TuHURA Biosciences, an oncology biotech, reflect the potential of its innovative platform. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Cancer cure
TuHURA Biosciences is an immuno-oncology company developing personalized therapeutic cancer vaccines that activate a patient's immune system. We classify the company as part of the "Cancer Treatment" sector. The chart below illustrates the overall dynamics of this high-risk but promising field.
Broad Market Index - GURU.Markets
TuHURA Biosciences is an oncology company developing personalized immunotherapies that help the immune system recognize and attack cancer cells. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
HURA - Daily change in the company's share price TuHURA Biosciences Inc.
For TuHURA Biosciences, Inc., an oncology biotech, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter for risk assessment formulas on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Cancer cure
TuHURA Biosciences, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with HURA's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
TuHURA Biosciences is an early-stage biotech company developing new cancer treatments. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TuHURA Biosciences Inc.
TuHURA Biosciences, Inc.'s year-over-year performance is a story of developing a new generation of cancer immunotherapy. Its 12-month market cap depends entirely on progress in clinical trials of its personalized vaccine and other drugs aimed at overcoming resistance to existing treatments.
Annual dynamics of market capitalization of the market segment - Cancer cure
TuHURA, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique developments in oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
TuHURA Biosciences is a clinical-stage biotech company whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TuHURA Biosciences Inc.
TuHURA Biosciences is an early-stage oncology company. Its monthly valuation is based almost entirely on investor confidence in its scientific platform. Fluctuations on the chart reflect progress in preclinical studies, patent announcements, or funding to advance to human trials.
Monthly dynamics of market capitalization of the market segment - Cancer cure
TuHURA Biosciences is a biotechnology company developing personalized immunotherapeutic drugs for cancer treatment that activate a patient's own immune system. The graph below shows the overall dynamics in the oncology sector, reflecting the ongoing search for new approaches to creating more effective cancer vaccines.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Early-stage biotech stocks are a venture bet on science. The chart below shows investors' overall risk appetite. Is TuHURA Biosciences moving at an extreme amplitude, amplifying market movements multiple times?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TuHURA Biosciences Inc.
Shares of TuHURA Biosciences, an oncology company, reflect progress in cancer immunotherapy on a weekly basis. The price movement is a response to clinical trial data from their personalized vaccines, which are designed to train the immune system to fight tumors.
Weekly dynamics of market capitalization of the market segment - Cancer cure
TuHURA Biosciences develops innovative cancer treatments. As an early-stage biotech, its value depends almost entirely on the prospects of its scientific developments. The chart below will show whether TuHURA's share price reflects unique company news or the general sentiment in the high-risk oncology startup sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
TuHURA Biosciences is a biotech company whose value depends on clinical trial results. Shares in this sector often move independently of the market. This chart will help you understand: do TuHURA shares follow the broader market or are news about its developments creating a completely independent trajectory?
Market capitalization of the company, segment and market as a whole
HURA - Market capitalization of the company TuHURA Biosciences Inc.
TuHURA Biosciences' market capitalization tells the story of an early-stage biotech company developing personalized cancer immunotherapy. Its speculative price chart reflects investors' faith in its unique approach. Its performance tells the story of science and the long journey through clinical trials, where every step can lead to a rise or a fall.
HURA - Share of the company's market capitalization TuHURA Biosciences Inc. within the market segment - Cancer cure
TuHURA Biosciences is a biopharmaceutical company working on personalized cancer immunotherapy. Its market capitalization within the sector reflects the market's valuation of its innovative approach. The chart shows its position among other companies seeking to harness a patient's immune system to fight tumors.
Market capitalization of the market segment - Cancer cure
TuHURA Biosciences is an early-stage biotech company developing new cancer treatments. The chart below shows the overall market capitalization of the oncology sector. Its dynamics reflect the massive investment in this field, where even small companies with promising ideas can attract attention.
Market capitalization of all companies included in a broad market index - GURU.Markets
TuHURA Biosciences is a biotech company working on new cancer treatments. The market capitalization of such companies reflects the hope of a scientific breakthrough. Their volatility on the overall chart reflects the fact that in biotech, the path from idea to approved drug is long and fraught with risk, but the potential reward is enormous.
Book value capitalization of the company, segment and market as a whole
HURA - Book value capitalization of the company TuHURA Biosciences Inc.
TuHURA Biosciences' book value is its capital, which is dedicated to developing personalized cancer vaccines and immunotherapies. This is the tangible, scientific foundation for a new approach to cancer treatment. How is this young biotech asset shaping up? The chart below shows its initial performance.
HURA - Share of the company's book capitalization TuHURA Biosciences Inc. within the market segment - Cancer cure
TuHURA Biosciences develops new cancer immunotherapy methods, which requires cutting-edge research laboratories. The chart shows the share of these science-intensive tangible assets in the biotech sector, reflecting the physical foundation of its innovative platform.
Market segment balance sheet capitalization - Cancer cure
TuHURA Biosciences is a biotech company at the forefront of the fight against cancer. Its main assets are its scientific platform and patents. A book value chart will show how "light" its capital base is, which is typical for R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
TuHURA Biosciences, Inc. is developing a new generation of cancer immunotherapy. Its book value reflects its unique technological platform and the capital needed to conduct clinical trials. The chart shows the material base upon which innovative approaches to cancer treatment are built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TuHURA Biosciences Inc.
TuHURA Biosciences' balance sheet is capital. Its market price reflects faith in its unique approach to cancer immunotherapy. The chart shows a "hope factor" that depends entirely on progress in clinical trials. This is a valuation of scientific potential, not assets.
Market to book capitalization ratio in a market segment - Cancer cure
TuHURA Biosciences is an oncology company developing new immunotherapies. Its valuation, like that of many biotech companies, is based on the promise of future breakthroughs. The chart shows the huge premium investors are paying for the hope of new cancer treatments.
Market to book capitalization ratio for the market as a whole
TuHURA Biosciences is an early-stage biotech company developing cancer vaccines and microbial therapies. Its assets are its scientific ideas and preclinical data. This chart shows the overall market valuation, but how do investors evaluate the potential of a company that combines several cutting-edge approaches to fighting cancer?
Debts of the company, segment and market as a whole
HURA - Company debts TuHURA Biosciences Inc.
TuHURA Biosciences, an early-stage biotech company, is developing new approaches to cancer treatment. Its financial strategy is entirely focused on funding research. This chart shows how it raises capital to test its innovative ideas in the lab and in preclinical models.
Market segment debts - Cancer cure
TuHURA Biosciences is an early-stage biotech company developing new approaches to cancer treatment. Such companies are almost always financed through equity capital due to the high risks. This chart shows how the company secures the resources to test its scientific hypotheses.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TuHURA Biosciences Inc.
TuHURA Biosciences is a biotech company developing cancer treatments. This chart shows its reliance on external financing. Like many companies in this field, debt is a vital source of funding for long-term, expensive clinical trials fraught with risk and uncertainty.
Market segment debt to market segment book capitalization - Cancer cure
TuHURA Biosciences is a clinical-stage oncology company developing personalized immunotherapy drugs. This chart shows the overall debt burden in the biotech sector. It helps understand how the industry finances its risky R&D and how TuHURA's financial model compares to this trend.
Debt to book value of all companies in the market
TuHURA Biosciences is developing new cancer treatments. It's an early-stage biotech company whose future depends on the results of clinical trials. The chart showing total debt is of little use here, as TuHURA's financial model is based not on debt but on venture capital and faith in scientific breakthroughs.
P/E of the company, segment and market as a whole
P/E - TuHURA Biosciences Inc.
For TuHURA Biosciences, Inc., a biopharmaceutical company, this chart illustrates investor expectations. Like many companies in the research stage, its value is based not on profits, but on the potential of its cancer treatment platform. It's an estimate of a future scientific breakthrough, coupled with the high risks of clinical trials.
P/E of the market segment - Cancer cure
Immuno-oncology, which TuHURA likely focuses on, is at the cutting edge of science. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that such companies are valued as scientific platforms, and their value is based on investor confidence in their technology, not on current financial performance.
P/E of the market as a whole
TuHURA Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its approach is aimed at overcoming resistance to existing treatments. This chart, showing overall risk appetite, allows you to assess how willing investors are to invest in TuHURA Biosciences' scientific innovations.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TuHURA Biosciences Inc.
TuHURA Biosciences is a clinical-stage biotech company developing personalized immunotherapeutics for cancer treatment. This chart reflects speculative expectations based on the potential of its unique technology. The trend represents the market's assessment of the likelihood of success in clinical trials.
%20P%2FE%20TuHURA%20Biosciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TuHURA-Biosciences-Inc.&v=1772682779851 "Chart of the company's future (projected) P/E TuHURA Biosciences Inc.")
Future (projected) P/E of the market segment - Cancer cure
TuHURA Biosciences is a biotech company developing personalized immunotherapeutic drugs for cancer treatment. This chart shows profitability expectations for the oncology sector. It provides insight into how investors view its unique approach to cancer vaccine development and its potential in this cutting-edge field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772682779910 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
TuHURA Biosciences, Inc. is a biopharmaceutical company developing personalized immunotherapies for cancer treatment. This chart illustrates investors' risk appetite. For a company operating at the forefront of oncology, it reflects the market's willingness to fund complex and expensive approaches to creating personalized cancer vaccines.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772682779960 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TuHURA Biosciences Inc.
TuHURA Biosciences, Inc. is an early-stage biotechnology company developing oncology therapies. The financial metrics presented here represent investments in preclinical research. This chart illustrates the initial phase of drug development, where the primary objective is to validate the scientific concept in a laboratory setting.
Profit of companies in the market segment - Cancer cure
TuHURA Biosciences is a biotechnology company developing personalized cancer vaccines based on mRNA technology. Its approach is aimed at activating the immune system against the unique mutations of a patient's tumor. This graph reflects the cutting-edge science and potential for profitability in oncology, where personalized medicine could become a new standard of care.
Overall market profit
TuHURA Biosciences is an early-stage biotech company developing personalized immunotherapeutic drugs for cancer. Its future depends on the success of its innovative technology and attracting investment. The overall economic climate, shown in this chart, influences investor willingness to invest in long-term, capital-intensive research projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TuHURA Biosciences Inc.
TuHURA Biosciences is a clinical-stage oncology company developing personalized immunotherapeutics. The earnings forecast in this chart reflects analyst expectations for the clinical trial results of its innovative platform.
%20profit%20of%20the%20company%20TuHURA%20Biosciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TuHURA-Biosciences-Inc.&v=1772682780447 "Graph of future (projected) profit of the company TuHURA Biosciences Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
TuHURA Biosciences is an oncology company developing personalized immunotherapy treatments. Their approach utilizes a patient's own tumor antigens to create a vaccine. This chart shows the revenue forecast for the cancer treatment sector, providing context for assessing the potential of TuHURA's breakthrough, yet complex, technologies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772682780552 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
TuHURA Biosciences is an early-stage biotech company. Its value and future depend entirely on the success of its scientific platform and its ability to attract funding. This graph, reflecting the overall risk appetite in the market, is critical for the availability of venture capital for such innovative but risky companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772682780620 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TuHURA Biosciences Inc.
TuHURA Biosciences is a biotechnology company developing personalized immunotherapeutics for cancer treatment. This chart shows a speculative estimate of its future potential. This estimate is a bet on the success of its innovative approach to cancer vaccine development.
P/S market segment - Cancer cure
TuHURA Biosciences is a clinical-stage immuno-oncology company developing personalized cancer vaccines. This chart shows the industry-average price-to-sales ratio. It reflects investor expectations for the company's innovative approach, which aims to overcome resistance to existing immunotherapies.
P/S of the market as a whole
TuHURA Biosciences is a clinical-stage biopharmaceutical company developing personalized immunotherapeutics for cancer treatment. Its approach is aimed at activating a patient's immune system against their unique tumor. This chart helps understand how the market is pricing these cutting-edge, yet complex and risky, approaches in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TuHURA Biosciences Inc.
TuHURA Biosciences is a biotech company developing personalized cancer immunotherapies. This chart shows its valuation relative to future, hypothetical, sales. It reflects investors' faith in its scientific approach and the potential to create personalized cancer vaccines for patients.
%20P%2FS%20TuHURA%20Biosciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TuHURA-Biosciences-Inc.&v=1772682780988 "The graph of the company's future (projected) P/S TuHURA Biosciences Inc.")
Future (projected) P/S of the market segment - Cancer cure
TuHURA Biosciences is a clinical-stage oncology company developing personalized immunotherapeutics that target cancer antigens unique to each patient. This chart reflects investor expectations for its cutting-edge scientific platform and potential for personalized medicine.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772682781019 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
TuHURA Biosciences is a biotech company developing personalized cancer vaccines. Its future depends entirely on the success of its scientific platform and clinical trials. This graph of HURA's overall expectations is merely a backdrop. The company's value is determined by faith in its technology, not the overall economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772682781090 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TuHURA Biosciences Inc.
This chart illustrates the financial trajectory of a biotech company. For TuHURA Biosciences, which develops personalized immuno-oncology therapies, it reflects funds raised from investors to fund clinical trials, not commercial sales revenue.
Sales of companies in the market segment - Cancer cure
TuHURA Biosciences, Inc. is a clinical-stage biotechnology company developing personalized immunotherapeutic drugs for the treatment of cancer. Its approach is aimed at activating the patient's own immune system. This chart shows the oncology sector's revenue, and the success of TuHURA's technology could become a breakthrough in personalized medicine.
Overall market sales
TuHURA Biosciences is a clinical-stage biotechnology company developing personalized immuno-oncology therapies. Its approach is based on using a patient's own cancer antigens to create a vaccine. This is cutting-edge science, and the company's success will mark a breakthrough in cancer treatment, advancing the entire healthcare sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TuHURA Biosciences Inc.
TuHURA Biosciences develops personalized immunotherapeutic drugs for cancer. Future sales projections depend on the success of its innovative platform and clinical trial results.
%20sales%20of%20the%20company%20TuHURA%20Biosciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TuHURA-Biosciences-Inc.&v=1772682781317 "Schedule of future (projected) sales of the company TuHURA Biosciences Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
TuHURA Biosciences, Inc. is a biotech company developing cancer treatments. The outlook for this vast sector highlights the ongoing search for new effective therapies. The chart reflects the overall investment climate and scientific trends within which the company is attempting to prove the effectiveness of its approach.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772682781329 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
TuHURA Biosciences is a biotechnology company developing personalized immunotherapeutic drugs for cancer treatment. Its success depends on the results of clinical trials. This overall economic activity graph does not affect treatment demand, but it is important for assessing the investment climate that influences biotech funding.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772682781474 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TuHURA Biosciences Inc.
TuHURA Biosciences is a clinical-stage oncology company developing personalized immunotherapy. Its financial performance is focused on research and development expenses. This chart shows not current profit, but rather the capital burn rate, a key metric for biotech companies seeking to bring a new product to market.
Market segment marginality - Cancer cure
TuHURA Biosciences, Inc. is a clinical-stage biotechnology company developing oncology therapies based on immune system activation. Its financial metrics reflect R&D expenditures. This chart provides insight into the company's operating model and level of investment in research compared to other oncology companies.
Market marginality as a whole
TuHURA Biosciences, Inc. is a clinical-stage biopharmaceutical company developing cancer treatments. This chart reflects average returns. In this context, TuHURA is a venture bet on a new scientific idea. The company has no revenue, and its financial metrics reflect research costs, not operating profitability.
Employees in the company, segment and market as a whole
Number of employees in the company TuHURA Biosciences Inc.
TuHURA Biosciences is a clinical-stage immuno-oncology company. Its extremely small team, comprised of key scientists and managers, is focused on advancing its developments. Any significant increase on this graph would indicate significant progress, such as successfully raising capital to expand clinical trials.
Share of the company's employees TuHURA Biosciences Inc. within the market segment - Cancer cure
TuHURA Biosciences is a clinical-stage biotechnology company developing personalized immunotherapeutics for cancer. This chart highlights its scientific focus. It reflects the percentage of immunologists and oncology specialists working on personalized vaccines and cell therapies that TuHURA attracts.
Number of employees in the market segment - Cancer cure
TuHURA Biosciences is an oncology company developing personalized immunotherapeutic vaccines. This graph illustrates the cutting edge of the fight against cancer. The growth of the research team here signifies progress in creating personalized vaccines that "train" the patient's immune system to recognize and attack their unique tumor.
Number of employees in the market as a whole
TuHURA Biosciences, Inc. is working on developing personalized cancer vaccines. This is at the cutting edge of science. For companies like these, the overall workforce schedule is irrelevant. Their development is funded by venture capital and depends solely on success in clinical trials. A scientific breakthrough is the only factor that drives the expansion of their research team.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TuHURA Biosciences Inc. (HURA)
TuHURA Biosciences is an oncology company developing personalized immunotherapeutic vaccines. This chart demonstrates how the market values cutting-edge medical technologies. The very high market capitalization per employee reflects the enormous potential of their scientific platform, where a small team of scientists can create a product capable of changing the paradigm of cancer treatment.
%20of%20the%20company%20TuHURA%20Biosciences%20Inc.%20(HURA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TuHURA-Biosciences-Inc.-HURA&v=1772682782085 "Chart of market capitalization per employee (in thousands of dollars) of the company TuHURA Biosciences Inc. (HURA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
TuHURA Biosciences is developing new cancer treatments. In this field, a company's value is essentially a measure of its scientific potential. This chart demonstrates the enormous value the market places on the intellectual contribution of each scientist on the team, expecting them to deliver breakthroughs that could change the paradigm of cancer treatment.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772682782101 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
TuHURA Biosciences develops new cancer immunotherapy methods. In biotech, value is determined by scientific potential. This graph reflects the high valuation per employee, as a small team of scientists is working on technologies that could radically change approaches to cancer treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772682782147 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TuHURA Biosciences Inc. (HURA)
TuHURA Biosciences is a biotech company developing immunotherapy for cancer treatment. Their approach is based on personalized vaccines and microbiome modification to enhance treatment response. This is cutting-edge R&D. This negative indicator shows how much the company is investing in each scientist to develop this complex, multi-component therapy.
%20Chart%20TuHURA%20Biosciences%20Inc.%20(HURA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TuHURA-Biosciences-Inc.-HURA&v=1772682782203 "Company Profit Per Employee (in thousands of dollars) Chart TuHURA Biosciences Inc. (HURA)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
TuHURA Biosciences (HURA) is a biotech company developing oncology treatments. As with other R&D firms, this timeline is a long shot. Profitability is negative during the research phase. HURA's entire value lies in its scientific team and pipeline, which could deliver breakthrough profitability in the future if their therapies prove successful.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772682782238 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
TuHURA Biosciences (HURA) is a biotech company working on cancer treatments. It is in the early, clinical stage. Its staff consists of scientists, and its profit per employee is deeply negative. The chart reflects the investment in the R&D team, which is trying to develop breakthrough treatments without currently having commercial products.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772682782326 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TuHURA Biosciences Inc. (HURA)
TuHURA Biosciences is an early-stage biotech company developing cancer therapies. This chart reflects its current focus on research. Lack of revenue is the norm. This metric demonstrates enormous potential: if successful, revenue per scientist could be astronomical, reflecting the value of innovation.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TuHURA-Biosciences-Inc.-HURA&v=1772682782355 "Sales chart per company employee TuHURA Biosciences Inc. (HURA)")
Sales per employee in the market segment - Cancer cure
TuHURA Biosciences is a biotech company developing cancer immunotherapy based on a combination of oncolytic viruses and vaccines. At the R&D stage, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee, which is critical for funding their complex platform.
Sales per employee for the market as a whole
TuHURA Biosciences is a clinical-stage biotech company developing cancer treatments, including therapeutic vaccines. It's an R&D business. This chart shows revenue per employee. Predictably, it's zero. It emphasizes that the company doesn't sell products, but rather invests in lengthy and expensive clinical trials, where its scientific staff creates future value.
Short shares by company, segment and market as a whole
Shares shorted by company TuHURA Biosciences Inc. (HURA)
TuHURA Biosciences is a biotech company developing cancer treatments, including personalized vaccines. This chart shows bearish bets. Bears are betting on an extremely high risk of clinical trial failure or that its approach to personalized vaccines will prove too complex and expensive to commercialize.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TuHURA-Biosciences-Inc.-HURA&v=1772682782870 "Short Shares Chart for the Company TuHURA Biosciences Inc. (HURA)")
Shares shorted by market segment - Cancer cure
TuHURA Biosciences is a biotech company focused on developing cancer immunotherapy. This chart shows overall short positions in the biotech sector. A high reading reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies (e.g., the FDA) across the sector.
Shares shorted by the overall market
TuHURA Biosciences (HURA) is a clinical-stage biotech company. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TuHURA Biosciences Inc. (HURA)
TuHURA Biosciences is a clinical-stage biotech company. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TuHURA-Biosciences-Inc.-HURA&v=1772682783110 "RSI 14 indicator chart for the company's stock TuHURA Biosciences Inc. (HURA)")
RSI 14 Market Segment - Cancer cure
TuHURA (HURA) is a biotech company, a cancer "hunter" (immuno-oncology). The "Cancer Cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is HURA's growth due to its R&D or is the entire biotech sector simply overheated by expectations?
RSI 14 for the overall market
For TuHURA Biosciences, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HURA (TuHURA Biosciences Inc.)
TuHURA Biosciences is a biotech company developing personalized immunotherapeutic cancer vaccines. This chart shows the average 12-month forecast of analysts, representing their collective speculative bet on the success of this complex early-stage R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HURA-TuHURA-Biosciences-Inc.&v=1772682783477 "A chart showing analyst consensus forecasts for the expected stock price. HURA (TuHURA Biosciences Inc.)")
The difference between the consensus estimate and the actual stock price HURA (TuHURA Biosciences Inc.)
TuHURA Biosciences (HURA) is a clinical-stage oncology company developing immunotherapy for cancer treatment. This chart is a classic biotech barometer. It measures the vast gap between the current speculative price and the analyst consensus price target. This gap reflects the enormous potential experts believe for the success of their R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HURA-TuHURA-Biosciences-Inc.&v=1772682783639 "A chart showing the difference between the consensus forecast and the actual stock price. HURA (TuHURA Biosciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
TuHURA Biosciences is a biotech company developing personalized cancer vaccines. Its technology aims to "train" the immune system to attack tumors. This chart shows analysts' overall expectations for the cancer treatment sector. It reflects whether experts believe personalized vaccines will be a breakthrough.
Analysts' consensus forecast for the overall market share price
TuHURA Biosciences is an early-stage biotech company developing personalized cancer vaccines and methods for overcoming resistance to immunotherapy. This chart shows the overall risk appetite. For TuHURA, a high-risk company, overall market optimism is critical to raising the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TuHURA Biosciences Inc.
TuHURA Biosciences is a clinical-stage biotech company working in the field of immuno-oncology. They are developing personalized cancer vaccines using a unique approach to activating the patient's immune system. This chart is a pure indicator of faith in their science. It does not reflect revenue, but rather a speculative estimate of their R&D progress and clinical trial data.
AKIMA Market Segment Index - Cancer cure
TuHURA Biosciences is an early-stage biotech company developing personalized cancer vaccines and methods for overcoming resistance to immunotherapy. This chart shows the average index for the oncology sector. It provides investors with a benchmark for how TuHURA, which is developing breakthrough technology, compares to the average.
The AKIM Index for the overall market
TuHURA Biosciences is a biotech company developing personalized cancer vaccines and innate immune inhibitors. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this new immuno-oncology platform.
